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Background: International partnerships in research are receiving ever greater attention, given that technology has
diminished the restriction of geographical barriers with the effects of globalisation becoming more evident, and
populations increasingly more mobile.
Discussion: In this article, we examine the merits and risks of such collaboration even when strict universal ethical
guidelines are maintained. There has been widespread examples of outcomes beneficial and detrimental for both
high and low –income countries which are often initially unintended.
Summary: The authors feel that extreme care and forethought should be exercised by all involved parties, despite
the fact that many implications from such international work can be extremely hard to predict. However ultimately
the benefits gained by enhancing medical research and philanthropy are too extensive to be ignored.
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The interest and ability to develop international partner-
ships in the pursuit of research goals is greater than ever,
especially with advances in technology and an increased
cultural awareness of common issues that face everyone
around the world.
It is now nearly universally accepted that with increas-
ingly mobile populations, health issues are less parochial
and are of global concern, given that cultural, social health
factors and diseases transcend borders. Communicable dis-
eases are not restricted by geography or borders with ever
growing migration as the current Ebola outbreak illustrates;
the NHS continues to look for low cost innovation, espe-
cially with recent economic stagnation; and globalisation
means the UK is increasingly less isolated in health and
economic terms. Thus, ‘Global Health’ has burgeoned from
its perception as a niche subject to core knowledge, as rein-
forced by ‘The Gold Guide’ [1], ‘Broadening Your Horizons’
produced by the BMA [2], and ‘Tomorrow’s Doctors’* Correspondence: Johnchetwood@doctors.org.uk
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undergraduate and postgraduate medical curricula.
There is also humanitarian need for international re-
search, as medical initiatives in low-income countries
are continually underfunded and underrepresented in
clinical medicine and research programmes, and the
greatest potential to improve life expectancy and quality
lies there – for example, with neglected vaccination ef-
forts for viral hepatitis B. However, there are certain
risks and considerations to international collaboration
and the influence from wealthy institutions. Research
findings from a higher-income country may be costly or
hard to implement in a lower-income country, may not
be culturally appropriate, and often these focus on non-
communicable diseases, prevalent in northern countries.
Therefore, there can be a tendency to neglect the spe-
cific local needs of lower-income countries.
In 2002, the Nuffield Council on Bioethics published its
report “The Ethics of Research Related to Health Care in
Developing Countries” [4]. This departs from the inter-
nationally accepted Declaration of Helsinki in that it ar-
gues it may be morally acceptable to establish paradigms
more applicable to the location of study albeit the ‘besttral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tem’, rather than developed world gold-standards.
However, such local standards are often aspirational,
rather than grounded in practicality, and open to inter-
pretation given a lack of national standards, protocols
and algorithms, particularly where the realities of health-
care depart from ideal guidelines.
In this article we examine the advantages and pitfalls
of such international work.Discussion
Refocusing research resources
In moral terms, international collaboration should move
research goals away from pure market forces and towards
humanitarian aims. The greatest need for increasing qual-
ity and length of life lies in low-income countries and co-
operation may result in a marriage of a high-income
world’s research capacity with access to a low-income
country’s population and health needs, for mutual benefit.
This problem of disproportionate spending on health re-
search, which neglects the poorest populations, came into
notoriety with the “10/90 gap” publications from the
Global Forum for Health Research (GFHR) [5] and has
persisted [6] despite the increasing role of such philan-
thropic foundations as the Wellcome Trust [7] and the Bill
and Melinda Gates Foundation [8].
First, this allows efforts to focus on debilitating dis-
eases that can have great improvements in health factors
from small investment rather than those which simply
provide good financial returns, as exemplified by such
private-public collaborations as the Medicines for Mal-
aria Venture (MMV), and organisations such as the
Schistosomiasis Control Initiative, which is consistently
rated as one of the most cost-effective charities in exist-
ence [9-13]. Second, this provides commercial viability
to research that might not otherwise be possible, where
afflicted populations are generally impoverished and
underserved by pharmaceutical interest, such as the
aptly named ‘neglected tropical diseases’ [14,15]. Third,
with international funding, expertise and equipment,
there is an increased scope in what the research itself
may achieve, for example with genetics or metabolomics
which require expensive equipment and specialist techni-
cians, but where diseases are more prevalent in lower-
income countries, concentration on these populations
may lead to quicker recruitment of patients. Last, inter-
national research may better control for genetic, social
and cultural bias present, than if examining just one popu-
lation. Information from larger areas and a larger span of
populations ensures a greater accuracy to the work itself.
Multicentre research validating metabolomic and prote-
omic biomarkers in liver disease, across diverse popula-
tions is an example of just such a success story [16-18].Nonetheless, such distortion, even if intended to be phil-
anthropic, can skew research outcomes to a high-income
country’s agenda [19]. Higher-income countries institu-
tions may lack insight into a lower-income partner coun-
try’s infrastructure, method of practice and make any
gains inefficient, or even impossible to be implemented
[4,20]. There also concerns that cultural differences can
lead to unintended ethical considerations such as whether
true informed consent is being collected [4,21], or what
intervention continues after a study ends [4], or whether
research efforts could be detracting from other potential
opportunities such as public health provision.
Examples of such healthcare inequalities, however
well meaning, are seen with international HIV-AIDS
work, owing to its relative funding, compared to other
more under-resourced diseases. WHO and World Bank
resources have been directed to provide heavily subsi-
dised ($20 per annum) or free HIV treatment, but many
of these drugs, such as tenofovir and lamivudine, are
also active against hepatitis B, a condition that does not
receive any subsidised funding. For example, in West
Africa, where deaths from the complications of hepatitis
B, such as hepatocellular carcinoma are very common,
patients with hepatitis B monoinfection must pay for
their own antiviral drugs. This is prohibitively expensive
for the majority of people, and often not regularly
feasible especially for more expensive, newer agents on
patent, such as tenofovir, which can cost upwards of
$8000 per annum. However, if an individual contracts
HIV, then their drugs, including antivirals, such as
tenofovir, are externally paid for by the Global Fund and
become free at the point of care [22,23]. In other words,
such inequalities in funding have a market distortion in
poorer African populations, where contracting an HIV
superinfection to viral hepatitis may improve their
prognosis, given that HIV positivity allows access to
definitive treatment for viral hepatitis too.
Similarly international partnership between the
North and the South may also cause the transfer of
resources away from governmental and market forces
that encourage delivering healthcare, and into
academically-driven research-directed goals that do
not directly and immediately benefit the population of
low-income nations – especially where national
research aims are not clearly established or adhered to.
This is particularly relevant when results are published
in peer-reviewed journals, but the countries in which
it may make the most impact may not have access to
these journals [24], or speak the same language - despite
the rise in open access journals [25], free online access
networks [24] and international journal partnerships
(such as JAMA and the Lancet which have created links
with African journals in order to boost African research
availability).
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national health arena should provide research questions
that are either in line with lower-income countries’ na-
tional priorities, or they should be in a position to justify
to external bodies the reasons why agendas do not com-
ply with criteria set out in the Nuffield report [4]. Con-
flict with different aims for research work may be
avoided with transparency and good communication.
Infrastructure and capacity building
Investment from external research bodies, including in-
dustrial partners, may allow the development of local
capacity. Foreign investment can also stimulate demand
for goods and services and therefore economic growth,
even those not directly associated with the research
work itself (for example local courier companies for
sample transport). This is in line with Keynesian view of
macroeconomics in the assertion that demand will
stimulate greater production to enter the market and
therefore a growth in the net size of the economy. A
greater wealth of the economy and therefore wealth per
capita, allows a greater expenditure on goods and ser-
vices that can benefit the individual (including in health),
as well as allows greater taxation revenue for public
provision, with greater marginal benefits seen at the
poorest ends of the spectrum.
Material investment is important in increasing re-
search structure and research potential (especially as
countries with higher GNP per capita generally spend a
larger percentage and absolute amount on medical re-
search and development [26,27]), but also critically,
international research causes the dissemination of know-
ledge, incentivising up-to-date information and stand-
ardisation of clinical practice. This effect is pronounced
with international healthcare studies with work opportun-
ities afforded as a result of the relationships developed.
This can be beneficial, both for low-income country staff
when they return with expertise in clinical and research
training, but also for high-income country staff, given that
access to populations in low-income countries with in-
creased disease prevalence allows research targets to be
reached more quickly. The Tropical Health and Education
Trust (THET) is one such organisation that creates a
framework for ‘health partnerships’, which are ostensibly
mutually beneficial. Such collaborations not only nurture
the dissemination of knowledge, but also can build on
multicentre research aims and opportunities.
On the other hand, when international placements be-
come feasible in research establishments in the North,
there is a risk of causing a ‘brain drain’, where skilled and
talented labour is permanently exported, depriving the do-
mestic healthcare system in lower-income countries. This
has contributed to situations, such as in Malawi where the
doctor to population ratio in 2008 was just 1.9 doctors to100 000 population [28], compared to the UK’s 2400 [29]
(although this issue is undoubtedly multifactorial includ-
ing training opportunities, provision of public resources,
poor equipment in rural areas, low pay, bureaucratic red
tape and political interference [30-32]). However the brain
drain issue is contentious, despite its clear rationale as an
argument, as staff may be viewed, as commodities, neither
taking their wishes for self-determination into account,
nor their quality of life.
Long-term placements in developed world institutions
also run the risk of over familiarizing healthcare profes-
sionals with alien healthcare systems that provide in-
appropriate experience. Many migrant workers, who
come to low-income countries for periods of research
or clinical training, have skill sets that are appropriate
for practice in their own countries, but all too often indi-
viduals find themselves ineffective and inexperienced in
inappropriate surroundings, and such experience in the
North may not improve their professional capacity if they
return home, given that disease prevalence and treatment
guidelines may differ. This may limit employment oppor-
tunities if domestic employers suspect returnees of being
unfamiliar or with outdated knowledge of accepted
methods of local clinical or research practice.
Medical expertise may also be retained in Europe,
North America or Japan. For example, if biomedical
samples are exported for analysis using expensive equip-
ment in high-income countries, there may be little
incentive to train local people in analytical techniques.
In an effort to develop division of labour, personnel
from lower-income countries may be practicing uncom-
plicated tasks that hinder their opportunity to engage in
novel research techniques available in their native
institutions. As Costello et al. [33] argue, ‘postal’
(sending biomedical samples) or ‘parachute’ research
(sending researchers on short-term placements) may
limit low-income countries involvement in the research
and provide an opportunity cost of the collaboration, if
there is not a concomitant sharing of the analysis.
In addition, research may have political, economic or
societal impacts beyond what was planned, especially
where cultural and social beliefs are ignored and where
healthcare aims are hijacked to high-income countries’
agendas. Unfortunately, high-income institutions often
take advantage of low-income countries in setting agendas
and may give the latter little or no credit in leading
international health partnerships. Furthermore, if there is
commercial value in the intellectual property then low-
income country institutions can be exploited financially as
well as intellectually [34].
Ultimately, it is often unlikely for many low-income
countries that the funding or infrastructure exists to
develop capacity without timely economic development
and long-term health structure investment. Although
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methods to improve global quality of life.
Producing high class research
As explained above, true partnership in international
health allows access to more diverse patient groups, with
different ethnicity and health behaviours. Larger patient
groups may enable enhanced patient recruitment, espe-
cially with rare diseases such as with Burkitts Lymph-
oma research in the 1950-60s [35], and can control for a
larger variety of local factors with the potential to create
higher powered research results.
Reputable high-ranking institutes may also lend credibil-
ity to research from high-income countries that would
otherwise be ignored as irrelevant or viewed with suspi-
cion in peer-reviewed journals when taking into account
the material’s source [36] (although true peer-review
should predominantly focus on the quality of the work it-
self), and bring important research into a more commonly
spoken language or higher impact-factor journals in wider
circulation and therefore to a wider audience [37].
Although there is often a financial cost to international
partnership with two-way visits and inspections, material
and sample transport between sites, and adherence to eth-
ical and/or clinical guidelines, relative costs, especially
for labour are often lower. The cost of international col-
laboration depends on the research involved. Financial as-
pects become more problematic either when relationships
crumble, sometimes leading to a significant loss of time
and money, or when exchange rates fluctuate which can
lead to unforeseen instability in budgetary planning.
Research across borders may also call for adherence to
different guidelines, with multiple ethics committee ap-
provals that increases red tape and make collaboration
difficult. However, this is really only a small barrier to
collaboration, rather than an argument against it.
There is often a perception that medical research in
lower-income countries takes place in areas with less
rigorous safety and ethical safeguarding to the detriment
of patient, and where errors are permitted to occur more
frequently. Although such a statement is so generalised as
to sometimes be true, frequently perceptions that low-
income countries cannot carry out high-class research
may lead to more stringent guidelines and safeguards.
This, in turn, can hinder an institution’s ability to carry
out research. Furthermore, this is mostly avoided when
many institutions carry out independent ethical review in
the partnering high-income country.
Summary
International research can certainly be problematic, and
will introduce foreseeable and unforeseeable difficulties.
Such efforts tend to fall on a spectrum - few people would
condone such work as AZT testing in Zimbabwe in the1990s [38] or the Turkegee experiments in the USA [39],
but without international collaboration neither would we
have the success stories of small pox or polio vaccination.
With rigorous planning, good ongoing communication
and transparency, adherence to internationally-accepted
ethical standards, and clear intended outcomes, common
problems can often be avoided. The benefits gained by en-
hancing medical research and philanthropy are too exten-
sive to be ignored, but do require extreme care and
forethought, despite the fact that many implications from
such international work can be extremely hard to predict.
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